Reactive oxygen species (ROS) are generated by virus-infected cells; however, the physiological importance of ROS generated under these conditions is unclear. Here we found that the inflammation and cell death induced by exposure of mice or cells to sources of ROS were not altered in the absence of canonical ROS-sensing pathways or known cell-death pathways. ROSinduced cell-death signaling involved interactions among the cellular ROS sensor and antioxidant factor KEAP1, the phosphatase PGAM5 and the proapoptotic factor AIFM1. Pgam5 -/mice showed exacerbated lung inflammation and proinflammatory cytokines in an ozone-exposure model.
R eactive nitrogen species and reactive oxygen species (ROS) such as ·O 2 and ··OH are generated as natural byproducts of normal oxygen metabolism. ROS serve an important role in cell signaling by regulating the proliferation and survival of cells 1, 2 . However, exposure to pollutants, an increased protein-folding load, elevated fatty-acid oxidation and energy metabolism can result in pathological accumulation of ROS in the endoplasmic reticulum, peroxisomes and mitochondria 3, 4 . Since oxidation by ROS can cause irreversible conformational changes to proteins and lipids, as well as DNA mutations 5 , several enzymatic and non-enzymatic mechanisms have evolved to protect cells from the detrimental accumulation of ROS.
The main intracellular sensor that monitors ROS is KEAP1 6 . Under physiological conditions, KEAP1 ubiquitinates and degrades the transcription factor NRF2, a positive regulator of the expression of genes encoding cytoprotective molecules. Increased intracellular ROS oxidizes KEAP1, which results in its inability to degrade NRF2; the latter then accumulates, translocates to the nucleus and induces the expression of antioxidant factors such as NQO1, HOX1 and TXN [7] [8] [9] [10] . Prolonged or considerable oxidative stress, however, does not induce sufficient expression of cytoprotective proteins and can result in cell damage and/or cell death 11 .
Exogenous stimuli such as ultraviolet light, heat or inflammatory cytokines increase intracellular ROS that contribute to the severity of pathological disorders 12, 13 . Furthermore, viral infection can increase intracellular ROS levels due to the perturbation of cellular metabolism 14, 15 . It has been proposed that in cases of persistent viral infection, ROS contribute to organ damage and exacerbate disease progression 16 . Some viruses have evolved mechanisms to avoid detrimental ROS generation to facilitate viral proliferation. For example, dengue virus 17 , human herpes virus 8 (Kaposi's sarcomaassociated herpesvirus (KSHV)) 18 and encephalomyocarditis virus 14 have evolved distinct mechanisms to modulate ROS-mediated celldeath pathways. Conversely, other viruses, such as Marburg virus, specifically perturb stress responses by promoting cytoprotective programs 19, 20 .
ROS-induced cell death can induce caspase-dependent apoptosis and inflammasome-driven pyroptosis, as well as caspase-independent cell-death pathways, including necroptosis, ferroptosis and autophagic cell death [21] [22] [23] [24] [25] . Despite the apparent importance of ROS in physiological and pathological processes, relatively little is known about their sensors and downstream signaling pathways that lead to cell death in response to oxidative stress. We demonstrate here a ROS-induced form of apoptosis-like cell death that we have called 'oxeiptosis' . This previously unknown form of cell death was independent of all previously characterized cell-death pathways and had an important role in limiting harmful ROS-associated inflammation.
Results
Ozone exposure induces inflammasome-independent inflammation in vivo. To investigate the involvement of known pathways in ROS-induced cell death, we used an in vivo ozone-exposure model (Fig. 1a) . A single exposure to ozone induced the accumulation of Fig. 1 | Inflammasome-, caspase-and necroptosis-independent but KeAP1-dependent cell death after stimulation with ROS. a, Cytospin quantification of neutrophils in the BALF of C57BL/6 mice (WT), Nlrp3 -/mice, Casp1 -/-Casp11 -/mice and Asc -/mice (n = 5 per genotype) 24 h after 1 h of exposure to air or to ozone at a dose of 1 ppm (key). b, Flow cytometry of MEFs given no pretreatment (Mock) or pretreated for 1 h with Z-VAD (20 μM) or Nec-7 (10 μM) (above plots), followed by 20 h of mock treatment or treatment with H 2 O 2 (left margin), assessed with the fluorogenic dye CytoCalcein, which is retained by living cells (a measure of viability), and phosphatidylserine (a measure of apoptosis). Numbers in outlined areas indicate percent cells with decreased CytoCalcein and/or increased phosphatidylserine. c, Resazurin-conversion assay of the viability of HeLa cells left untreated (control (Ctrl)) or treated for 1 h with Z-VAD or Nec-7 or both, or with 1 μM ferrostatin-1 (Fer-1) (horizontal axis), followed by 21 h of mock treatment or exposure to 0.5 mM H 2 O 2 (key); results presented as relative fluorescence units (RFU). d, Immunoblot analysis of full-length caspase-8 (arrowhead), cleaved caspase-8 (*) or the p18 fragment of caspase-8 (#) (right margin) in cells left untreated (-) or treated for 1 h with 20 µM Z-VAD (+) (above lanes), followed by 10 h of no further treatment (far left lane) or treatment with TRAIL (300 ng/ml) or H 2 O 2 (0.1 mM or 0.5 mM) (above blot). Left margin, size markers, in kilodaltons. e, Immunoblot analysis of RIPK3, the pseudo-kinase MLKL and β-actin (loading control) in lysates of THP-1 human monocytic cells and HeLa cells (above lanes). f, Resazurin-conversion assay (as in c) of HeLa cells pretreated with various concentrations (horizontal axis) of CRID3, followed by mock treatment or exposure to 0.5 mM H 2 O 2 (key). g, Resazurin-conversion assay (as in c) of HeLa cells pretreated with a combination of the inhibitors Z-VAD, 5 μM necrosulfonamide and ferrostatin-1 (+) or not (-) (horizontal axis), followed by mock treatment or stimulation with H 2 O 2 (0.5 mM or 2 mM) or staurosporine (STS) (below plot). h, Resazurin-conversion assay (left; as in c) of HeLa cells transfected for 48 h with control (non-targeting) siRNA with a scrambled sequence (siScr) or siRNA targeting KEAP1 (siKEAP1) or both KEAP1 and NRF2 (siKEAP1 + siNRF2) (key), followed by mock treatment or exposure to 0.5 mM H 2 O 2 (below plot); right, immunoblot analysis of KEAP1, NRF2 and β-actin (below blots) in cells as at left (colors above lanes match colors in key). i, Expression of the NRF2-regulated target genes NQO1 and TXN1 (key) in cells after 21 h of treatment with 0.5 mM or 1 mM H 2 O 2 (horizontal axis); results are presented relative to those of cells not treated with H 2 O 2 . Each symbol (a,c,g-i) represents an individual mouse (a) or measurement (c,g-i); small horizontal lines (a) indicate the mean (±s.e.m.). NS, not significant (P > 0.05); *P < 0.001 and **P < 0.0001 (two-tailed Mann Whitney test (a) or two-way analysis of variance (ANOVA) (c,g,h)). Data are from one experiment representative of at least three experiments (a-e,g,h) or two experiments (f,h) with similar results (mean ± s.d. of six technical replicates in c,f-h). ROS in mouse airway cells in vivo and led to severe inflammation, as indicated by an increased abundance of proteins, lymphocytes and cytokines in bronchoalveolar lavage fluid (BALF) of ozonetreated mice 26 ( Fig. 1a and Supplementary Fig. 1a,b ). In this in vivo model, the ozone-driven inflammation in mice that lacked key components of the inflammasome pathway such as NLRP3 (Nlrp3 -/-), caspase-1 and caspase-11 (Casp1 -/-Casp11 -/-) or the adaptor ASC (Asc -/-) was not significantly different from that of wild-type mice ( Fig. 1a ). Furthermore, caspase-3 and caspase-7, which are required for apoptosis, are not activated after a single exposure to ozone 27, 28 . Thus, in this experimental model, it was not clear which pathways were involved in ozone-mediated injury, inflammation or cell death.
Caspase-independent and kinase RIPK3-independent ROSinduced cell death. To investigate the pathways involved in ROSmediated cell death in greater detail, we studied cell survival in response to the ROS inducer hydrogen peroxide (H 2 O 2 ). Mouse embryonic fibroblasts (MEFs) exposed to H 2 O 2 showed lower viability than that of untreated MEFs (Fig. 1b ). Induction of cell death was not changed by pre-treatment with the caspase inhibitor Z-VAD or the necroptosis inhibitor Nec-7 ( Fig. 1b ). Furthermore, we assessed the morphology of MEFs by electron microscopy after exposure of the cells to H 2 O 2 . After treatment with H 2 O 2 , cells showed apoptotic membrane blebbing, which was also present in Z-VAD-treated cells exposed to H 2 O 2 ( Supplementary  Fig. 1c ). To confirm those data in different cell lines, we assessed the sensitivity of HeLa human cervical cancer cells and Jurkat human T lymphocytes to H 2 O 2 . As expected, treatment with H 2 O 2 induced cell death, as measured by a resazurin-reduction assay, an ATP-abundance assay, a tetrazolium dye (MTT) assay and a lactate dehydrogenase-release assay ( Fig. 1c and Supplementary  Fig. 1d-f ). Z-VAD was not able to restore cell viability ( Fig. 1c and Supplementary Fig. 1f ), despite successful inhibition of the cleavage of caspase-8 ( Fig. 1d ); this suggested a caspase-independent process. HeLa cells are naturally deficient in the kinase RIPK3 ( Fig. 1e ), a central component of the necroptosis pathway. Moreover, in line with published data 29 , pretreatment of cells with Nec-7 or a combination of Nec-7 plus Z-VAD did not rescue the cells from H 2 O 2 -induced death (Fig. 1c ). The ferroptosis inhibitor ferrostatin-1 also did not rescue cells from H 2 O 2 -triggered death ( Fig. 1c and Supplementary Fig. 1h ,i). Furthermore, the concentrations of H 2 O 2 used did not lead to the accumulation of LC3-A, an indicator of autophagic cell death ( Supplementary Fig. 1g ), nor did the chemical inhibition of inflammasomes by CRID3 produce an effect ( Fig. 1f ). Combining inhibitors of apoptosis, necroptosis and ferroptosis did not influence H 2 O 2 -induced toxicity ( Fig. 1g ). Collectively, our data suggested that H 2 O 2 -induced cell death could be mediated by a pathway independent of caspases, ferroptosis, pyroptosis, autophagy or necroptosis.
KEAP1 is required for H 2 O 2 -induced cell death.
A protein that directly links sensing of ROS to cell death has not been identified thus far. However, a well-studied sensor of ROS is KEAP1. KEAP1 contains carboxy-terminal cysteine residues that are oxidized by ROS and mediate a conformational change in the protein that results in the release of NRF2 for regulation of the expression of genes encoding cytoprotective molecules, to counterbalance oxidative stress 30 . We aimed to establish cellular systems with differential sensitivity to ROS; therefore, we depleted HeLa cells of KEAP1 and NRF2 and assessed their survival after treatment with H 2 O 2 . As expected, cellular depletion of KEAP1 led to upregulation of genes encoding cytoprotective molecules relative to their expression in control cells without such depletion ( Supplementary Fig. 1j ), and it significantly decreased cell death after treatment with H 2 O 2 (Fig. 1h ). Depleting cells of both KEAP1 and NRF2, which we expected would increase sensitivity to H 2 O 2 , also rescued cells from H 2 O 2 -induced death ( Fig. 1h ), despite no detectable upregulation of genes encoding cytoprotective molecules ( Supplementary Fig. 1j ). Moreover, expression of NRF2-dependent genes was increased by low concentrations of H 2 O 2 , while toxic concentrations of H 2 O 2 did not increase gene expression ( Fig. 1i ). Collectively, we concluded that the transcriptional activity NRF2 was dispensable for cytoprotection after depletion of KEAP1, which suggested that KEAP1 is a concentration-dependent ROS sensor with an active role in a ROSdependent cell-death pathway. KEAP1 utilizes PGAM5 to mediate ROS-induced cell death. We next sought to identify potential interaction partners of KEAP1 that could convey signals that lead to cell death. Using affinity purification followed by tandem mass spectrometry (AP-LC-MS/MS), we identified 32 proteins for which KEAP1 purifications showed significant enrichment, relative to the abundance of an unrelated control protein ( Fig. 2a and Supplementary Table 1 ). These 32 proteins included 14 known binding partners of KEAP1, including NRF2 ( Fig. 2a ). Only one protein identified had been previously associated with cell-death pathways: the phosphatase PGAM5 ( Fig. 2a ). PGAM5 is a convergence point of multiple cell-death pathways and has been shown to be involved in ROS-induced cell death 29 . PGAM5 bears an amino-terminal mitochondrial localization signal and transmembrane domain. Furthermore, PGAM5 interacts with KEAP1 and tethers it to the mitochondrial membrane 31 . We confirmed the association of KEAP1 with PGAM5 by co-immunoprecipitation of KEAP1 (tagged with streptavidin II and hemagglutinin (SII-HA)) with endogenous PGAM5 (Fig. 2b) , as well as by co-immunoprecipitation of SII-HA-tagged PGAM5 with endogenous KEAP1 (Fig. 2c ), and confirmed that amino acids 69-89 of PGAM5 were critical for its interaction with KEAP1 31 ( Supplementary Fig. 2a ). KEAP1 releases NRF2 after exposure to ROS and thereby allows accumulation of NRF2. This prompted us to investigate whether the interaction between KEAP1 and PGAM5 was similarly regulated by ROS. Indeed, binding of PGAM5 to KEAP1 was reduced in the presence of 0.5 mM H 2 O 2 , while nontoxic amounts of H 2 O 2 , which regulated NRF2-dependent gene expression ( Fig. 1h ,i), did not affect the interaction between KEAP1 and PGAM5 ( Fig. 2c ). KEAP1 and PGAM5 localized together with the mitochondrial marker COX IV under steady-state conditions 32 ( Supplementary Fig. 2b ). In the presence of 0.5 mM H 2 O 2 , only KEAP1, not PGAM5, lost its localization together with COX IV ( Supplementary Fig. 2b ), which further supported the proposal of a ROS-sensitive interaction between KEAP1 and PGAM5.
To determine functionally whether PGAM5 is involved in ROS-mediated cell death, we used small interfering RNA (siRNA)mediated knockdown of PGAM5 and assessed the cells by a flow cytometry-based cell-survival assay after treatment with H 2 O 2 . In HeLa cells transfected with control (non-targeting) siRNA, treatment with H 2 O 2 led to the death of 33% and 67% cells after 15 h and 20 h, respectively ( Fig. 2d ). Depleting cells of PGAM5 rescued the majority of cells from death; only 10% and 13% of the cells showed signs death at 15 h and 20 h, respectively, after treatment with H 2 O 2 (Fig. 2d ). Similarly, reduction enzyme activity was substantially decreased ( < 10%) in cells transfected with control siRNA and treated with H 2 O 2 , while cells lacking PGAM5 showed more than 73% activity ( Fig. 2e and Supplementary Fig. 2c,d ). Depleting cells of both PGAM5 and NRF2 also rescued them from H 2 O 2induced death ( Fig. 2e ). While depleting cells of PGAM5 rescued them from H 2 O 2 -induced death, it did not affect the induction of apoptosis by staurosporin or the induction of necroptosis by Z-VAD plus TNF and mildly affected ferroptosis induced by the tyrosine kinase inhibitor sorafenib and autophagic cell death triggered by the electron-transport-chain accelerator CCCP ( Fig. 2f ). Inhibition of caspases in cells depleted of PGAM5 did not further increase cell viability ( Supplementary Fig. 2e ), which further excluded the possibility of apoptosis in this experimental setting. These data collectively suggested that depleting HeLa cells of PGAM5 did not produce a general effect but was specific for H 2 O 2 -induced cell death. We reproduced these data in a genetically 'clean' system; Pgam5 +/+ and Pgam5 +/-MEFs ( Supplementary Fig. 2f ) treated with H 2 O 2 showed severe signs of cytotoxicity ( Fig. 2g ). Morphologically, these cells showed membrane blebbing (Fig. 2h ), a classic indicator of apoptotic cell death. However, Pgam5 -/-MEFs tolerated treatment with a high dose of H 2 O 2 (Fig. 2g ) and were morphologically similar to untreated MEFs (Fig. 2h ). Sorafenib decreased the viability of Pgam5 +/-MEFs and Pgam5 -/-MEFs similarly ( Supplementary  Fig. 2g ). We concluded that PGAM5 was specifically involved in an H 2 O 2 -induced signaling cascade unrelated to other known celldeath pathways.
PGAM5-dependent cell-death induction utilizes AIFM1. PGAM5
has been proposed to be of central importance to the transmission of cell-death signals 29 , but its molecular partners are not known. AP-LC-MS/MS with PGAM5 as bait identified eight interacting pro-teins with high confidence ( Fig. 3a and Supplementary Table 2 ). As expected, PGAM5 associated with KEAP1 ( Fig. 3a ). Furthermore, PGAM5 precipitated together with proteins of the TIM complex (TIMM50, TIMM8A and TIMM13), which facilitates the transport of proteins to the inner mitochondrial membrane 33 . Among the proteins identified as interacting with PGAM5, only HAX1 ('HCLS1associated protein X-1') and AIFM1 have been previously associated with cell-death pathways (Fig. 3a) . Notably, AIFM1 has previously been linked to caspase-independent cell death 34 . We confirmed the PGAM5-AIFM1 interaction by co-precipitation followed by immunoblot analysis (Fig. 3b ). Studies of AIFM1 mutants lacking various domains indicated that AIFM1 bound to PGAM5 through its amino-terminal domains (amino acids 2-103), which include the mitochondrial localization signal and the transmembrane domain, while carboxy-terminal sequences (amino acids 480-613) were not involved in its binding to PGAM5 ( Supplementary Fig. 3a ).To investigate whether AIFM1 serves as a downstream target of PGAM5, we depleted HeLa cells of AIFM1 or PGAM5 and monitored their survival after stimulation with H 2 O 2 or the mitochondrial ROS inducer tBHQ. As expected, cells treated with the control siRNA were highly sensitive to treatment with H 2 O 2 and tBHQ ( Fig. 3c and Supplementary Fig. 3b ). Notably, HeLa cells and SKN-BE2 human neuroblastoma cells depleted of AIFM1 or PGAM5 exhibited survival rates superior to those of control cells after treatment with H 2 O 2 and tBHQ ( Fig. 3c and Supplementary Fig. 3b, c) . Combined depletion of KEAP1, PGAM5 and AIFM1 did not significantly increase viability in response to treatment with H 2 O 2 , relative to the viability of cells depleted of only one of these molecules ( Supplementary  Fig. 3d ), which suggested that all three proteins were operating in the same pathway. AIFM1 has been described to be central for the oxidoreductase pathway 35 . However, the mitochondrial respiration of HeLa cells left untreated or treated with various doses of H 2 O 2 was indistinguishable ( Supplementary Fig. 3e ), which suggested that death-inducing amounts of intracellular ROS were independent of the oxidoreductase function of AIFM1.
PGAM5 dephosphorylates AIFM1 Ser116. We next investigated the functional interaction between PGAM5 and AIFM1. Notably, the binding of AIFM1 to PGAM5 was reduced when cells were treated with H 2 O 2 (Fig. 4a) . The binding was restored by the ROS scavenger N-acetylcysteine (Fig. 4a ), which suggested that ROS can modulate the interaction between PGAM5 and AIFM1. PGAM5 is reported to have serine-threonine-phosphatase activity 29 , and several studies have shown that processed substrates often lose interaction with their modifying enzymes 31 . Notably, binding of PGAM5 to AIFM1 was also diminished in the absence of phosphatase inhibitors (Fig. 4b) . We replaced residues known to be phosphorylated in the amino-terminal region of AIFM1 (as identified online at https://www.phosphosite.org) with alanine and assessed their ability to precipitate together with endogenous PGAM5. Replacement of the serine at position 116 of AIFM1 with alanine (S116A) impaired the binding of AIFM1 to PGAM5, whereas replacement of other residues did not affect the association with PGAM5 ( Fig. 4c ). Sequence-alignment analysis revealed notable conservation of AIFM1 Ser116 and surrounding amino acid residues among mammals ( Fig. 4d and Supplementary Fig. 4a ). Of particular interest in this region were two glutamic acid residues (which contribute negative charges) located three and five amino acids carboxy-terminally of Ser116 ( Fig. 4d and Supplementary Fig. 4a ). Such contribution of negative charges has been reported to support the binding of substrates to the positively charged phosphatase active site of PGAM5 36 ( Supplementary Fig. 4c ). A 'custom-raised' antibody to AIFM1 phosphorylated at Ser116 indicated that Ser116 was phosphorylated under steady-state conditions ( Fig. 4e and Supplementary Fig. 4b ). Strikingly, treatment of cells with H 2 O 2 led to dephosphorylation of phosphorylated Ser116 (Fig. 4e ).
We generated recombinant PGAM5 and a phosphatase-inactive PGAM5 mutant unable to form dimers (PGAM5(F244D)) ( Fig. 4f and Supplementary Fig. 4d -f,h) in order to assess the phosphatase activity of PGAM5. PGAM5 lacking amino acids 2-28 (PGAM5Δ2-28) was able to release phosphates from phosphorylated serine residues but not from pseudo-substrate peptides with phosphorylated threonine residues, while PGAM5Δ2-28(F244D) was inactive in this context ( Supplementary Fig. 4i ). Dephosphorylation of the pseudo-substrates was inhibited by the phosphatase inhibitor sodium orthovanadate ( Supplementary Fig. 4i ). We proceeded using membrane-bound lysates of HeLa cells as a substrate for recombinant PGAM5. Treatment of the membranes with recombinant proteins, followed by staining for phosphorylated AIFM1, showed that incubation with PGAM5Δ2-28 led to dephosphorylation of AIFM1 phosphorylated at Ser116 (Fig. 4g ). This process was inhibited by sodium orthovanadate and sodium fluoride (Fig. 4g) . The mutant protein PGAM5Δ2-28(F244D) did not dephosphorylate AIFM1 phosphorylated at Ser116 (Fig. 4g ). The effect of recombinant PGAM5 was specific for AIFM1 phosphorylated at Ser116, since the kinase p38 was not dephosphorylated in this assay.
To assess the consequences of the dephosphorylation of AIFM1 Ser116 on cell survival, we reconstituted HEK293 human embryonic kidney cells in which AIFM1 was knocked out via CRISPR-Cas9 with expression plasmids for AIFM1, the mutant AIFM1(S116A) that cannot be phosphorylated or the mutant AIFM1(S116D) that mimics phosphorylation and monitored their survival. Expression of AIFM1(S116A) was sufficient to induce cell death, as indicated by rounding up of the cells and reduced levels of intracellular ATP, but expression of AIFM1(S116D) was not (Fig. 4h,i) .
The data reported above showed that AIFM1 phosphorylated at Ser116 was dephosphorylated during oxidative stress and that PGAM5 was able to mediate this dephosphorylation. Furthermore, they highlighted the dephosphorylation of AIFM1 Ser116 as a hallmark of this cell-death pathway. We call this 'oxeiptosis' , as it involves a cell-death pathway ('-ptosis') that can be triggered by oxidative stress.
Pgam5 -/mice show severe inflammation in response to ozone treatment. In order to gain information about the role of PGAM5 in vivo, we assessed the response of Pgam5 +/+ mice (as a control) and Pgam5 -/mice to the ROS inducer ozone. We exposed Pgam5 +/+ and Pgam5 -/mice to ozone and assessed inflammation parameters 4 h and 24 h later. Treatment with ozone led to a greater abundance of protein in the BALF of Pgam5 -/mice than in that of Pgam5 +/+ mice ( Fig. 5a and Supplementary Fig. 5a ). Specifically, we noted significantly more myeloperoxidase, an inflammation-specific marker generated by myeloid cells, in the BALF of Pgam5 -/mice than in that of Pgam5 +/+ mice (Fig. 5a ). Ant increase in inflammation was confirmed by the greater total number of cells in the BALF of ozone-treated Pgam5 -/mice than in that of their Pgam5 +/+ counterparts, most strikingly a significantly greater number of neutrophils in Pgam5 -/mice than in Pgam5 +/+ mice ( Fig. 5b and Supplementary  Fig. 5b ). The BALF of ozone-treated Pgam5 -/mice had significantly higher concentrations of the cytokine IL-6 and the chemokines CXCL1, CXCL2 and CCL2 than did that of their Pgam5 +/+ counterparts ( Fig. 5c ). Collectively, these data indicated that PGAM5 deficiency in mice led to increased inflammation after exposure to an inducer of ROS. This suggested that PGAM5 is needed to dampen inflammatory responses and that the absence of PGAM5 in vivo leads to compensatory inflammatory responses. 18 , which can lead to cell death. As a countermeasure, many viruses regulate cell-death pathways in order to optimize their own replication and spread. Mining an AP-MS data set that identified cellular binding partners of regulators in the innate immune system 37 for molecules that interact with KEAP1, PGAM5 or AIFM1 revealed four proteins from distantly related viruses that interacted with any of these three proteins (Fig. 6a ). VP24 of Marburg virus bound KEAP1 19, 38 ; VΔC of measles virus and K3 of KSHV associated with PGAM5 ( Supplementary Fig. 6a-d and Supplementary Table 3 ); and the non-structural protein NSs of La Crosse virus bound AIFM1 ( Supplementary Fig. 6e,f) . In additional interaction studies of the non-structural protein NS2 of respiratory syncytial virus, we identified the PGAM5-interaction site (amino acids 2-55) of AIFM1 as a cellular target ( Supplementary Fig. 6g-i and Supplementary  Table 4 ). We proceeded to functionally assess the interaction of K3 (KSHV) and PGAM5. The binding of PGAM5 to K3 required amino acids 29-69 of PGAM5 ( Supplementary Fig. 6d ), a region that has previously been identified as being important for full PGAM5 functionality 36 . Precipitates of SII-HA-PGAM5 from cells co-expressing K3 showed diminished phosphatase activity (Fig. 6b) , which confirmed the functional interaction between PGAM5 and K3. Collectively, these data indicated that distantly related viruses shared an ability to bind KEAP1, PGAM5 or AIFM1, suggestive of evolutionary pressure to target this pathway.
Oxeiptosis is targeted by viral open reading frames. Viral infection commonly triggers the generation of intracellular ROS

PGAM5 regulates virus-induced inflammation in vivo. We used infection with influenza A virus (FluAV) as model to assess the involvement of oxeiptosis in viral infection. HeLa cells infected
with FluAV strain SC35M showed accumulation of intracellular ROS (Fig. 6c ) and expression of genes encoding cytoprotective molecules ( Supplementary Fig. 6j ). Furthermore, infection with FluAV led to less phosphorylation of AIFM1 at Ser116 than that of unin-fected control cells (Fig. 6d) , indicative of the activation of oxeiptosis. In line with that, HeLa cells depleted of PGAM5 (via siRNA) showed significantly less FluAV-induced cytotoxicity than that of cells treated with control siRNA ( Supplementary Fig. 6k) . Similarly, infection of Pgam5 -/-MEFs with FluAV resulted in survival rates superior to those of FluAV-infected Pgam5 +/+ or Pgam5 +/-(control) cells (Fig. 6e ), indicative of a role for PGAM5 in virus-induced cell death in vitro. To assess the function of PGAM5 in vivo, we infected Pgam5 +/+ , Pgam5 +/and Pgam5 -/mice with 1,500 plaque-forming units of FluAV. This infection regime caused only 10% mortality in Pgam5 +/+ and Pgam5 +/mice (Fig. 6f) . In contrast, Pgam5 -/mice showed a markedly greater mortality rate, since 78% of these mice succumbed to infection with FluAV (Fig. 6f) . Surprisingly, viral titers and levels of viral mRNA in the lungs of Pgam5 +/mice on days 3 and 5 after infection were indistinguishable from those in Pgam5 -/mice ( Fig. 6g and Supplementary Fig. 6l ), which suggested that PGAM5 did not directly affect viral replication and that the increased susceptibility to infection to FluAV was not due to an exacerbated viral load. However, in line with the results of the ozone-exposure experiments (Fig. 5c ), mouse lungs showed significantly more Il6 mRNA in the absence of PGAM5 than in its presence ( Supplementary Fig. 6m) . Similarly, the BALF of FluAVinfected Pgam5 -/mice contained more protein (Fig. 6h ) and significantly more inflammatory cytokines such as IL-6, CXCL1 and CCL2 ( Fig. 6i and Supplementary Fig. 6n ) than that of FluAVinfected Pgam5 +/mice. These experiments suggested exacerbated inflammatory processes during infection with FluAV in the absence of PGAM5. Indeed, histological analysis of the lungs of FluAV-infected mice showed more-severe lung pathology, with significantly more destruction of the epithelial layer in the bronchioles and more infiltration of lymphocytes in Pgam5 -/mice than in Pgam5 +/mice (Fig. 6j ). However, immunohistochemistry analyzing the distribution of FluAV proteins in the lungs of infected mice showed much deeper infiltration of FluAV in Pgam5 -/mice than in Pgam5 +/mice (Fig. 6k ). From these experiments, we concluded that PGAM5 was needed to modulate inflammatory responses in vivo and that lack of PGAM5 in the context of infection with FluAV resulted in acute necrotic intrabronchial and peribronchial inflammation, which allowed deeper infiltration of the virus.
DISCuSSION
Cells have to make critical 'decisions' about how to respond to physiological and pathological insults. Infections, inflammatory cytokines and other environmental cues can raise ROS levels to detrimental concentrations that contribute to pathological disease manifestations 16, 39, 40 . However, a dedicated sensor of ROS that is linked to cell death or mediates inflammatory responses has not been described thus far. Here we found that the well-described ROS sensor KEAP1 induced a cell-death pathway that signaled through PGAM5 and AIFM1.
Interestingly, KEAP1 bears 27 cysteine residues in its carboxyl terminus, which can be modified in a stimulus-dependent manner 6 . These cysteine residues not only might allow sensing of the presence or absence of ROS but also might be able to quantify ROS and induce concentration-specific responses. Such a system might allow a single protein to integrate quantitative information in order to regulate diverse cellular signaling pathways and to respond to environmental needs in an appropriate manner. That model is supported by the finding of dissociation of KEAP1 and PGAM5 that was observed only in the presence of a high concentration of H 2 O 2 , while concentrations that activated KEAP1-dependent activation of NRF2 did not perturb this interaction. This would probably explain the dual characteristics of KEAP1 in regulating NRF2dependent protection at low levels of ROS while mediating the induction of cell death through the release of PGAM5 at high levels of oxidative stress.
PGAM5 has been proposed to function at a convergence point of multiple caspase-independent cell death pathways 29 . Notably, cell-death stimuli reported to signal through PGAM5, such as TNF, H 2 O 2 , t-butyl hydroxide and A23187, have all been shown to generate intracellular ROS 41, 42 , which might explain the ability of PGAM5 to integrate many diverse cell-death signals.
The signaling downstream of PGAM5 that results in cell death remains unknown. By AP-LC-MS/MS analysis, we identified AIFM1 as a binding partner of PGAM5. AIFM1 resides inside mitochondria and thus should be spatially dissociated from PGAM5. However, KEAP1 is reported to be tethered to the outer membrane of mitochondria through engagement of PGAM5 32 . Conversely, the same mechanism could mediate retention of PGAM5 at the outer mitochondrial membrane in order to spatially dissociate it from its phosphatase target, AIFM1. Interestingly, PGAM5 bears a CX9C motif (two cysteine residues separated by nine irrelevant amino acids (X9), in the region from Cys229 to Cys239) that can be used by the Mia40 complex to import proteins into mitochondria 43 . In line with the possibility of an activity in mitochondria, PGAM5 physically interacts with members of the TIMM complex (TIMM8 and TIMM13), which is known to be involved in regulating protein import into mitochondria 33 . Release of PGAM5 by KEAP1 during oxidative stress might be part of an activation process that allows internalization of PGAM5 into the mitochondria so it can interact with its target AIFM1. We identified the highly conserved residue Ser116 in AIFM1 as a target of the phosphatase activity of PGAM5. PGAM5 dephosphorylated AIFM1 at Ser116 during treatment with large amounts of H 2 O 2 and during the course of viral infection. Functionally, expression of AIFM1(S116A) was sufficient to induce death of AIFM1-deficient cells.
On the basis of those data, we propose the existence of a caspaseindependent cell-death pathway, which we have called 'oxeiptosis' . This pathway encompasses KEAP1-PGAM5-AIFM1 and is activated by detrimental levels of ROS. Dephosphorylated AIFM1 Ser116 serves as a marker and is at the same time a key regulator of the activity of the oxeiptosis pathway.
An increase in oxidative stress has been linked to necroptosis, apoptosis, ferroptosis, autophagy and pyroptosis 44, 45 . These pathways operate in parallel and integrate additional signals. The engagement of these pathways is also cell type dependent, since some of the individual pathways are limited to certain cell types. We propose that oxeiptosis operates in parallel with other cell-death pathways and leads to a non-inflammatory, caspase-independent, apoptosis-like cell-death phenotype. It is operational in a wide range of cells, with the possible exception of macrophages, since PGAM5 deficiency has been reported to be dispensable for ROS-dependent death in these cells 46 . In line with the possibility of an apoptosis-like antiinflammatory activity for PGAM5 in vitro, Pgam5 -/mice showed increased inflammatory parameters in their BALF after exposure to ozone or infection with FluAV.
ROS are produced during many disorders, including allergy, autoimmunity, allograft rejection, cancer and infection with pathogens, which suggests that oxeiptosis might be activated in many different pathological situations 47 . Notably, it has been shown that treatment of tumors with ROS-inducing agents such as BZL101 induces cell death in an AIFM1-dependent manner 48 . Keap1 is often mutated in lung, gallbladder and head-and-neck cancers, and Keap1 expression is silenced by hypermethylation of its promoter in various cell lines derived from lung and prostate cancers 49 ; this could lead to dysfunction of the oxeiptosis pathway and could thereby promote the survival of transformed cells. Similarly, evolutionary distinct viruses interfered with KEAP1, PGAM5 and AIFM1. This indicated that modulation of oxeiptosis is involved in antiviral immunity. Indeed, we identified an important role for PGAM5 during infection with FluAV, and PGAM5 deficiency in mice led to increased inflammatory responses.
Published reports suggest activation of RIPK3-dependent necroptosis by FluAV, and FluAV-infected Ripk3 -/mice show decreased inflammatory parameters in their lungs 50 . It is likely that the pro-inflammatory phenotype of FluAV-infected Pgam5 -/mice was mediated by compensatory activation of Ripk3-dependent necroptosis.
An important complication of treating virus-derived tumors might be the activity of viral proteins, such as the K3 protein of KSHV, which directly affected the functionality of PGAM5.
Our study has identified oxeiptosis, a ROS-induced cell-death pathway that leads to a caspase-independent non-inflammatory cell death and encompasses KEAP1, PGAM5 and AIFM1. Similar to viral interference with KEAP1, PGAM5 or AIFM1, we propose that targeting oxeiptosis through therapeutic intervention might constitute a means with which to modulate the progression of diseases that involve oxidative stress.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-017-0013-y.
Cloning and expression of recombinant proteins and phosphatase assay.
Amino-terminal His-tagged PGAM5 (pNIC28-Bsa4-PGAM5(Δ2-28)) (PDB accession code 3MXO) was provided by A. Chaikuad and S. Knapp (University of Oxford). For solubility reasons, the recombinant protein carried a deletion of amino acids 2-28. The substitution F244D was introduced into PGAM5 by sitedirected mutagenesis. Sequences of all cloning primers are available on request. Expression of recombinant proteins was induced overnight at 18 °C in Escherichia coli strain Rosetta(DE3) using 0.5 mM IPTG (Thermo). Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 8.5, 500 mM NaCl, 10% glycerol, 40 mM imidazole, 1 mM DTT and protease inhibitor cocktail (EDTA-free, cOmplete; Roche)) using an Emulsiflex-C3 homogenizer, and cleared lysate was used for protein purification using a HisTrap HP column (GE Healthcare: 17-5247-01) and was further purified by gel filtration (mobile phase: 30 mM Tris-HCl, pH 8.5, 300 mM NaCl, 10% glycerol and 1 mM DTT). Identity of recombinant PGAM5Δ2-28 wild-type and PGAM5Δ2-28(F244D) was confirmed by mass spectrometry. Far ultraviolet (UV) circular dichroism (CD) spectra of wild type and a mutant version of PGAM5 were recorded on a Jasco J-810 CD-Photometer at room temperature in 20 mM sodium phosphate buffer, pH 7.4,and 50 mM NaF. For each sample and the buffer (baseline), four scans were recorded and averaged. The averaged baseline spectrum was subtracted from the averaged sample spectra and the resulting spectra were smoothed using an FFT filter (as part of the software package). Measurements were made only down to wavelengths where the instrument dynode voltage indicated the detector was still in its linear range (190 nm). Spectra are shown as the mean residue elipticity. Secondary structure compositions were estimated using the CONTINLL program 53 .
To determine phosphatase activity in vitro of affinity purified proteins, beads with bound proteins were resuspended in ddH 2 O and were incubated in phosphatase buffer (50 mM imidazole, pH 7.2, 0.2 mM EGTA, 0.02% β-mercaptoethanol and 0.1 mg/ml BSA) and 50 μM phosphorylated peptide (peptide sequences: RRA(pT)VA and AAL(pS)ASE) for 20 min at 30 °C. The reaction was stopped by addition of Malachite Green Reagent as described before 42 . After 15 min of incubation at room temperature, absorbance at 630 nm was measured using an Infinite 200 PRO series micro plate reader (Tecan). To determine phosphatase activity in silico, recombinant proteins were used incubated in phosphatase buffer as described above. To detect dephosphorylation of AIFM1, HeLa cell lysate was separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membranes were incubated with recombinant PGAM5Δ2-28 wild-type and PGAM5Δ2-28(F244D) in phosphatase buffer for 60 min at 30 °C, washed, blocked and stained with primary antibodies.
Cell-viability assays, flow cytometry and immunofluorescence. To test cell viability, we used three different assays. We measured ATP levels by CellTiter-Glo assay according to the manufacturer's protocol. We measured the activity of released lactate dehydrogenase by a lactate dehydrogenase assay according to the manufacturer's protocol. We measured succinate dehydrogenase mitochondrial activity by an MTT assay. In brief, 0.5 mg/ml MTT was added to the cells and incubated for 3 h at 37 °C; the reaction was stopped by aspiration of the medium and solving the crystals in 1:1 mix of DMSO/ethanol for 15 min shaking at room temperature, followed by measurement of absorbance (570 nm) using an Infinite 200 PRO series micro plate reader (Tecan). We measured general enzymereduction activity by a resazurin-based cell-viability assay. 50 μg/ml resazurin was added to each well of a 96-well plate and incubated for 30 min at 37 °C, followed by measurement of fluorescence (535/590 nm) using an Infinite 200 PRO series micro plate reader (Tecan). Flow-cytometry-based cell-death assays were performed using the apoptosis-necrosis assay according to the manufacturer's instructions. To measure intracellular ROS, cells were incubated for 30 min with 1 μM CM-H 2 DCFDA in the dark and were fixed using 4% paraformaldehyde. Flow cytometry analyses were done using a FACSCalibur (BD) or MACSQuant analyzer (Miltenyi). For immunofluorescence, HeLa cells were grown on coverslips and fixed with 4% (w/v) paraformaldehyde for 15 min, permeabilized with 0.1% (v/v) Triton X-100 for 5 min and washed three times with blocking buffer (1 × PBS containing 0.1% FCS (w/v)). Immunofluorescence analysis was performed as described previously 2 . Confocal imaging was performed using a LSM780 confocal laser scanning microscope (ZEISS, Jena, Germany) equipped with a Plan-APO 63x/NA1.46 oilimmersion objective (ZEISS).
Real-time RT-PCR. RNA was reverse-transcribed with PrimeScript RT Master Mix (TAKARA) and quantified by real-time RT-PCR using the QuantiFast SYBR Green RT-PCR Kit (Qiagen) and a CFX96 Touch Real-Time PCR Detection System (BioRad). Each cycle consisted of 10 s at 95 °C and 30 s at 60 °C, followed by melting-curve analysis. Primer sequences were as follows: huGAPDH (5′-GATTCCACCCATGGCAAATTC-3′ and 5′-AGCATCGCCCCACTTGATT-3′), hTBP (5′-GTTCTGAATAGGCTGTGGGG-3′ and 5′-ACAACAGCCTGCCACCTTAC-3′), KEAP1 (5′-GCTGATGAGGGTCACCAGTT-3′ and 5′-CCAACTTCGCTGAGCAGATT-3′), NRF2 (5′-GCTCATACTCTTTCCGTCGC-3′ and 5′-ATCATGATGGACTTGGAGCTG-3′), NQO1 (5′-GCATAGAGGTCCGACTCCAC-3′ and 5′-GGACTGCACCAGAGCCAT-3′), TXN (5′-AATGTTGGCATGCATTTGAC-3′ and 5′-CCTTGCAAAATGATCAAGCC-3′), mIL6 (5′-TAGTCCTTCCTACCCCAATTTCC-3′ and 5′-TTGGTCCTTAGCCACTCCTTC-3′) and NS1 (5′-GACCAGGCGATCATGGATAA-3′ and 5′-TGCTTCTCCAAGCGAATCTC-3′).
Affinity purification and quantitative LC-MS/MS, bioinformatics analysis.
For affinity purification, cell lysates were prepared by lysing cells for 5 min on ice in TAP lysis buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 5% (v/v) glycerol, 0.2% (v/v) Nonidet-P40, 1.5 mM MgCl 2 and protease inhibitor cocktail (EDTA-free, cOmplete; Roche)) or Cell Signaling IP buffer (20 mM TrisHCl, pH 7.5, 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton and protease inhibitor cocktail (EDTA-free, cOmplete; Roche)). Where indicated, phosphatase inhibitor cocktail (PhosSTOP; Roche) or sodium fluoride (NaF) and sodium orthovanatade were added. For affinity purification with HA-SII-tagged proteins, streptavidin affinity resin was incubated with cell lysate in either TAP lysis buffer or Cell Signaling IP buffer for 60 min at 4 °C on a rotary wheel. For affinity purification with Flag-M2tagged proteins, Flag-M2 affinity resin was incubated with cell lysate and processed as above. Beads were washed four times with TAP lysis buffer, followed by two times with TAP wash buffer (lacking 0.2% (v/v) Nonidet-P40) or five times with Cell Signaling IP buffer, boiled in 2x Cell Signaling SDS buffer for 5 min at 95 °C and subjected to SDS-PAGE and immunoblot analysis. For LUMIER experiments, cell lysates (1:10 diluted in TAP wash buffer) or beads were resuspended in TAP wash buffer and transferred in 4 × 20 μl aliquots to white well plate (Nunc) and mixed with 2x Renilla reagent (100 mM K 3 PO 4 , 500 mM NaCl, 1 mM EDTA, 25 mM thiourea and 30 µM coelenterazine), and luminescence was measured using an Infinite 200 PRO series micro plate reader (Tecan).
To detect and quantify proteins bound to HA-SII-tagged bait proteins by affinity purification and mass spectrometry, samples were prepared as described above. After the final four washes in TAP lysis buffer, samples were in addition washed four times with TAP wash buffer to remove residual detergent. Four independent affinity purifications were performed for each bait. Sample preparations and LC-MS/MS analysis was performed as described previously 51 . In brief, samples were sequentially digested with LysC (Wako Chemicals USA) and Trypsin (Promega), acidified with 0.1% TFA, desalted with C18 stage tips and analyzed by liquid chromatography coupled to mass spectrometry on an Orbitrap XL platform (Thermo Fisher Scientific).
For analysis of interaction proteomics data, mass spectrometry raw files were processed with MaxQuant version 1.3.0.5 or 1.4.0.6 54 using the built-in Andromeda engine to search against human proteome (UniprotKB, release 2012_06) containing forward and reverse sequences. In MaxQuant, the label-free quantitation (LFQ) algorithm 55 and Match Between Runs option were used as described previously 51 . Only proteins identified on the basis of at least two peptides and a minimum of three quantitation events in at least one experimental group were considered. LFQ protein intensity values were log-transformed, and missing values were filled by imputation. Specific enrichment was determined by multiple equal variance t-tests with permutation-based false-discovery rate (FDR) statistics, performing 250 permutations. FDR thresholds and S 0 parameters were empirically set to separate background from specifically enriched proteins. Data was analyzed using Perseus version 1.5.2.11. Results were plotted using R (www.R-project.org). Sequence logo was generated using WebLogo 56 .
Mitochondrial respiration. HeLa cells were mock treated or treated with 0.1 mM or 0.5 mM H 2 O 2 for 5 h. After 5 h, medium was changed to SeaHorse Assay medium (DMEM D5030 with 10 mM pyruvate and 2 mM glutamine) without H 2 O 2 treatment. After 1 h, read out in a SeaHorse Analyzer was performed with injections of 1.5 μM OliogA (ATP coupler) after 24 min, 1 μM CCCP (carbonyl cyanide m-chlorophenyl hydrazone; electron-transport-chain accelerator) after 45 min and 4 μM antimycin A and 2 μM rotenone (mitochondrial inhibitors) after 69 min. Results were normalized by total DNA using CyQuant.
Electron microscopy. MEFs were treated as indicated, than were washed once and fixed with glutaraldehyde. Fixed cells were washed with 0.2 M sodium cacodylate, osmicated with 1% OSO 4 for 40 min, washed twice and subsequently dehydrated in ethanol and infiltrated with Low Viscosity Embedding Media Spurr's Kit (Electron Microscopy Sciences, cat.# E14300) according to the manual. After polymerization (overnight at 70-80 °C), ultrathin serial sections (thickness, 60 nm) were counterstained with 0.5% uranyl acetate and 3% lead citrate. Images were acquired with JEOL JEM-1230 transmission electron microscope (magnification 5000-30000x), with 80 kV, Gatan Orius SC1000 digital Camera and software Gatan DigitalMicrograph™.
In vivo experiments. Heterozygous Pgam5-deficient mice (Pgam5 +/-) on the C57BL/6 N background were obtained from the European Mouse Mutant Archive (EMMA). Mice were bred at the MPI of Biochemistry animal facility under license number 55.2-54-2532.116.2015. Primer sequences for genotyping were as follows: L3f_6764 5′-AGGCTGGATCACTATAAGGC-3′ and L3r_6765 5′-CTGGAGACATTGTGACCATC-3′. Asc -/mice (C57BL/6 J), Nlrp3 -/mice (C57BL/6 J), Casp1 -/-Casp11 -/mice (SV129 background) or wild-type mice (C57BL/6 J) were housed and bred in the animal facility at Transgenose Institute (TAAM-CNRS, Orléans, France, UPS 44 under agreement D-45-234-6, 2014) under SPF conditions in a temperature-controlled environment with free access to food and water. All animal experiments have been performed according to animal welfare regulations and have been approved by the responsible authorities (University Freiburg, Germany, G-12/46, CNRS Orleans, France, CLE CCO 2012-047). For ozone-treatment experiments, mice were exposed to ozone (1 ppm) for 1 h in a Plexiglas chamber (EMB 104, EMMS). An ozonisator (Ozoniser S 500 mg, Sander) was used to generate ozone, and ozone levels were controlled by an ozone sensor (ATI 2-wire transmitter, Analytical Technology). Mice were euthanatized 4 h or 24 h after ozone exposure by progressive CO 2 inhalation. BALF was collected, and cardiac perfusion was performed with ISOTON II (Acid free balanced electrolyte solution Beckman Coulter, Krefeld, Germany) before removal of lungs for further analysis. BALF was isolated by four consecutive saline lavages (500 µl per lavage; 0.9% NaCl) via a cannula introduced into the trachea. After centrifugation (2,000 rpm for 10 min at 4 °C), the supernatants were removed and stored at -20 °C for ELISA, and cell pellets were analyzed by Cytopsin (Thermo Scientific, Waltham, USA) followed by Diff-Quick coloration (Merz & Dade A.G., Dudingen, Switzerland). Differential cell counts were performed with at least 400 cells. For FluAV-infection experiments, mice were anesthetized with ketamine (100 μg per gram body weight) and xylazine (5 μg per gram body weight) before infection by the intranasal route with 1.5 × 10 3 plaqueforming units of SC35M per animal in a 40 μl volume. Mice were monitored for weight for 14 d and were euthanized when they lost > 25% of their initial body weight.
Measurement of infection, cell death and inflammatory parameters in vivo.
Mouse myeloperoxidase was assessed by ELISA (R&D Systems, Abingdon, UK), cytokines were measured by Multiplex Immunoassay (ProcartaPlex, eBioscience) and total protein levels in BALF were analyzed using the Bio-Rad DC Protein Assay according to the manufacturer's instructions.
For histological analyses, the left lobes of the lungs were fixed in 4% buffered formaldehyde and embedded in paraffin. After tissue sections (3 μm), cuts were stained with hematoxylin and eosin. Epithelial damage and inflammatory cell infiltration were assigned scores for severity of epithelial injury and inflammation (0-5) 57 . Lungs were stained with anti-FluAV antiserum, ApopTag Fluorescein In situ Apoptosis Detection Kit (Merck) and DAPI.
RNA-mediated knockdown. Duplex siRNAs (1nmol of siRNA per 1 × 10 6 cells) were transfected using the Neon Transfection System (Invitrogen) according to the manufacturer´s instructions for HeLa and SKN-BE2 cells. siRNAs were purchased from Qiagen or Dharmacon or were synthesized by the Core Facility at the MPI of Biochemistry. siRNA target sequences were as follows: human PGAM5 (#1: 5′-CCCGCCCGTGTCTCATTGGAA-3′; #2: 5′-TCCAAGCTGGACCACTACAAA-3′; #3: 5′-CTCGGCCGTGGCGGTAGGGAA-3′; #4: 5′-CGCTAGTGACAGCCCAATAT-3′; #5: 5′-GGAGAAACCAATATAGAATT-3′), human AIFM1 (#1: 5′-GAACATCTTTAACCGAATG-3′; #2: 5′-GCATGAAGATCTCAATGAA-3′; #3: 5′-CAAGGAAGATCATTAAGGA-3′; #4: 5′-GGTAGAAACTGACCACATA-3"; #5: 5′-GATCAAGTCCTTTGTG-3"; #6: 5′-CCTGAGAGGAGGTCGA-3"; #7: 5′-GGAATTGGCAAACCCAC-3"; #8: 5′-GGAGGTCGAATGGGTA-3′), human KEAP1 (#1: 5′-GGACAAACCGCCTTAATTC-3′; #2: 5′-CAGCAGAACTGTACCTGTT-3′; #3: 5′-GGGCGTGGCTGTCCTCAAT-3′; #4: 5′-CGAATGATCACAGCAATGA-3′), human NFE2L2 (#1: 5′-TAAAGTGGCTGCTGAGAAT-3′; #2: 5′-GAGTTACAGTGTCTTAATA-3′; #3: 5′-TGGAGTAAGTCGAGAAGTA-3′; #4: 5′-CACCTTATATCTCGAAGTT-3′) and scrambled (5′-AAGGTAATTGCGCGTGCAACT-3).
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Experimental design 1. Sample size
Describe how sample size was determined. Sample size was chosen to generate solid data that allows statistical analysis of the data. Replicates varied between 3 to up to 24 . The sample size, data distribution are described associated statistics are well described in Figure legends.
Data exclusions
Describe any data exclusions.
No data was excluded, no animals were excluded
Replication
Describe whether the experimental findings were reliably reproduced.
All data was reliably reproduced. The number of repeats is mentioned in Figure  legends 
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. mice were allocated into groups according to their genotypes. No randomisation was used.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was used.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
